Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.

Bimzelx (bimekizumab-bkzx) - UCB

http://www.ncbi.nlm.nih.gov/pubmed/42128532

Atul Deodhar; Chetan Prajapati; Christine de la Loge; Helena Marzo-Ortega; Karl Gaffney; Maureen Dubreuil; Philip J Mease; Sarah Kavanagh; Uta Kiltz; Victoria Navarro-Compán

May 18, 2026